Eli Lilly’s Fourth-Quarter Earnings Report: What to Expect

Eli Lilly's Fourth-Quarter Earnings Report: What to Expect

Eli Lilly and Company (LLY: NYE) is due to release its fourth-quarter earnings report this week. As investors eagerly await the update, industry experts offer their insights on what to expect from the company’s financial performance.

 

Eli Lilly’s Growth Prospects: J.P. Morgan Analysis Reveals

Leading analyst Chris Schott from J.P. Morgan has underscored growth prospects for Eli Lilly deriving from the success of Mounjaro and the potential of donanemab, a pioneering treatment set for launch in 2025. Schott’s estimate for fourth-quarter revenue is $8.97 billion, attributing significant revenue contribution to Mounjaro. Nonetheless, Zepbound sales are predicted to be moderate.

LLY Ratings by Stock Target Advisor

Looking to the future, Eli Lilly’s revenue growth for 2024 is projected by Schott at 16% year-over-year with the company’s incretin franchise forecasted to achieve $50 billion by 2030.

 

Stock Target Advisor’s Analysis on Eli Lilly:

Stock Target Advisor maintains a ‘Hold’ stance on Eli Lilly’s stock with a target price of 0 and envisions no price change over a 12-month period. However, the average analyst target price for Eli Lilly over the next year stands at $631.37 with a consensus rating of ‘Strong Buy.’ When it comes to Stock Target Advisor’s analysis, the view is Neutral, backed by 9 positive signals against 10 negative signals.

The company’s stock price has witnessed a surge of +28.40% over the preceding week, +53.15% over the last month, and +96.90% over the past year. These developments denote superior risk-adjusted returns and positive cash flow for Eli Lilly.

The Drug Manufacturers – General sector, inclusive of Eli Lilly, has been rated as ‘Neutral’ by Stock Target Advisor with average returns of -1.14% spanning a month.

 

Conclusion:

Eli Lilly’s forthcoming earnings report carries the potential to steer the company’s trajectory in 2024. Investors are encouraged to closely keep tabs on the company’s financial performance and the resulting impact of key products on its revenue and profitability.

Top Trending Stocks

AVG Analyst Rating STA Analysis
StockTargetAdvisor
Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
N/A
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Very Bullish
N/A
StockTargetAdvisor
Bearish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Slightly Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Bullish
StockTargetAdvisor
Strong Buy
StockTargetAdvisor
Neutral
Ad
Ad

Leave a Reply

Your email address will not be published. Required fields are marked *